Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.72
AMRN's Cash-to-Debt is ranked lower than
82% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. AMRN: 0.72 )
Ranked among companies with meaningful Cash-to-Debt only.
AMRN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.93 Max: No Debt
Current: 0.72
0.07
No Debt
Equity-to-Asset -0.25
AMRN's Equity-to-Asset is ranked lower than
95% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. AMRN: -0.25 )
Ranked among companies with meaningful Equity-to-Asset only.
AMRN' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.11  Med: -0.15 Max: 0.83
Current: -0.25
-1.11
0.83
Debt-to-Equity -2.15
AMRN's Debt-to-Equity is ranked lower than
99.99% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. AMRN: -2.15 )
Ranked among companies with meaningful Debt-to-Equity only.
AMRN' s Debt-to-Equity Range Over the Past 10 Years
Min: -58.54  Med: -1.56 Max: 3441.66
Current: -2.15
-58.54
3441.66
Debt-to-EBITDA -1.38
AMRN's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. AMRN: -1.38 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AMRN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.7  Med: -1.95 Max: -0.02
Current: -1.38
-5.7
-0.02
Piotroski F-Score: 4
Altman Z-Score: 3.53
Beneish M-Score: -3.35
WACC vs ROIC
0.40%
496.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -40.63
AMRN's Operating Margin % is ranked higher than
60% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. AMRN: -40.63 )
Ranked among companies with meaningful Operating Margin % only.
AMRN' s Operating Margin % Range Over the Past 10 Years
Min: -691.08  Med: -120.14 Max: -25.15
Current: -40.63
-691.08
-25.15
Net Margin % -51.15
AMRN's Net Margin % is ranked higher than
58% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. AMRN: -51.15 )
Ranked among companies with meaningful Net Margin % only.
AMRN' s Net Margin % Range Over the Past 10 Years
Min: -630.82  Med: -103.99 Max: -37.47
Current: -51.15
-630.82
-37.47
ROA % -54.91
AMRN's ROA % is ranked lower than
62% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. AMRN: -54.91 )
Ranked among companies with meaningful ROA % only.
AMRN' s ROA % Range Over the Past 10 Years
Min: -549.69  Med: -62.23 Max: -26.61
Current: -54.91
-549.69
-26.61
ROC (Joel Greenblatt) % -239502.89
AMRN's ROC (Joel Greenblatt) % is ranked lower than
98% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. AMRN: -239502.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMRN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -239502.89  Med: -6691.67 Max: -1589.44
Current: -239502.89
-239502.89
-1589.44
3-Year Revenue Growth Rate 29.00
AMRN's 3-Year Revenue Growth Rate is ranked higher than
82% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. AMRN: 29.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMRN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -72.25 Max: 57.2
Current: 29
0
57.2
3-Year EBITDA Growth Rate 10.50
AMRN's 3-Year EBITDA Growth Rate is ranked higher than
61% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. AMRN: 10.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AMRN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 12.7 Max: 80.8
Current: 10.5
0
80.8
3-Year EPS without NRI Growth Rate 11.40
AMRN's 3-Year EPS without NRI Growth Rate is ranked higher than
56% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. AMRN: 11.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AMRN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 11.75 Max: 81.1
Current: 11.4
0
81.1
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMRN's 30-Y Financials

Financials (Next Earnings Date: 2019-02-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

AMRN Guru Trades in Q4 2017

Steven Cohen 250,000 sh (New)
Pioneer Investments 13,800 sh (New)
Paul Tudor Jones 11,196 sh (-0.06%)
Jim Simons 2,242,400 sh (-33.04%)
» More
Q1 2018

AMRN Guru Trades in Q1 2018

Paul Tudor Jones 19,596 sh (+75.03%)
Jim Simons 2,602,135 sh (+16.04%)
Steven Cohen Sold Out
Pioneer Investments Sold Out
» More
Q2 2018

AMRN Guru Trades in Q2 2018

Paul Tudor Jones Sold Out
Jim Simons 1,769,225 sh (-32.01%)
» More
Q3 2018

AMRN Guru Trades in Q3 2018

Steven Cohen 2,605,299 sh (New)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:AMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:SZSE:300497, ROCO:4105, NAS:ABEO, NAS:ARMO, TPE:6541, NAS:LXRX, NAS:URGN, XKRX:102940, XKRX:096530, TSE:2931, XSWX:BSLN, OSTO:WTX, OSTO:RECI B, NAS:NTLA, TSE:4593, SZSE:000518, SZSE:300147, OCSE:BAVA, XPAR:GNFT, BOM:540701 » details
Traded in other countries:EH3A.Germany,
Headquarter Location:Ireland
Amarin Corp PLC is a biopharmaceutical company with expertise in lipid science. The company is engaged in commercialization and development of therapeutics to improve cardiovascular health.

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its products include Vascepa. The firm has Development and Commercialization of Vascepa operating segment. It mainly operates in the United States.

Top Ranked Articles about Amarin Corp PLC

Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference
Market Trends Toward New Normal in Amarin, BioSpecifics Technologies, Cavco Industries, Iconix Brand Group, A-Mark Precious Metals, and Core-Mark Holding — Emerging Consolidated Expectations, Analyst Ratings
Amarin Prices Public Offering of American Depositary Shares
Amarin Prices Public Offering of American Depositary Shares
Amarin Announces Proposed Public Offering of American Depositary Shares
Amarin to Present at the Evercore ISI HealthCONx Conference
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amarin Corporation - AMRN
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composit
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composit

Ratios

vs
industry
vs
history
PS Ratio 23.39
AMRN's PS Ratio is ranked higher than
76% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMRN: 23.39 )
Ranked among companies with meaningful PS Ratio only.
AMRN' s PS Ratio Range Over the Past 10 Years
Min: 2.82  Med: 5.43 Max: 565.33
Current: 23.39
2.82
565.33
EV-to-EBIT -66.89
AMRN's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. AMRN: -66.89 )
Ranked among companies with meaningful EV-to-EBIT only.
AMRN' s EV-to-EBIT Range Over the Past 10 Years
Min: -82.2  Med: -11 Max: -2.1
Current: -66.89
-82.2
-2.1
EV-to-EBITDA -67.47
AMRN's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. AMRN: -67.47 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMRN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -82.9  Med: -11.1 Max: -2.2
Current: -67.47
-82.9
-2.2
EV-to-Revenue 26.95
AMRN's EV-to-Revenue is ranked higher than
75% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. AMRN: 26.95 )
Ranked among companies with meaningful EV-to-Revenue only.
AMRN' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.1  Med: 6.8 Max: 585
Current: 26.95
4.1
585
Current Ratio 1.33
AMRN's Current Ratio is ranked lower than
83% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. AMRN: 1.33 )
Ranked among companies with meaningful Current Ratio only.
AMRN' s Current Ratio Range Over the Past 10 Years
Min: 0.27  Med: 3.39 Max: 35.14
Current: 1.33
0.27
35.14
Quick Ratio 1.05
AMRN's Quick Ratio is ranked lower than
84% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. AMRN: 1.05 )
Ranked among companies with meaningful Quick Ratio only.
AMRN' s Quick Ratio Range Over the Past 10 Years
Min: 0.22  Med: 3.17 Max: 35.14
Current: 1.05
0.22
35.14
Days Inventory 257.01
AMRN's Days Inventory is ranked lower than
78% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. AMRN: 257.01 )
Ranked among companies with meaningful Days Inventory only.
AMRN' s Days Inventory Range Over the Past 10 Years
Min: 206.11  Med: 214.21 Max: 650.68
Current: 257.01
206.11
650.68
Days Sales Outstanding 84.53
AMRN's Days Sales Outstanding is ranked lower than
71% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. AMRN: 84.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMRN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.49  Med: 56.08 Max: 91.33
Current: 84.53
50.49
91.33
Days Payable 189.30
AMRN's Days Payable is ranked higher than
84% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. AMRN: 189.30 )
Ranked among companies with meaningful Days Payable only.
AMRN' s Days Payable Range Over the Past 10 Years
Min: 64.39  Med: 151.9 Max: 204.25
Current: 189.3
64.39
204.25

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -15.80
AMRN's 3-Year Average Share Buyback Ratio is ranked lower than
56% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. AMRN: -15.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMRN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -271.2  Med: -27.75 Max: 21.2
Current: -15.8
-271.2
21.2

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 4.32
AMRN's Price-to-Median-PS-Value is ranked higher than
93% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. AMRN: 4.32 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMRN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.06  Med: 0.78 Max: 92.63
Current: 4.32
0.06
92.63
Earnings Yield (Greenblatt) % -1.52
AMRN's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. AMRN: -1.52 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMRN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -46.7  Med: -9.1 Max: -1.2
Current: -1.52
-46.7
-1.2

More Statistics

Revenue (TTM) (Mil) $205.75
EPS (TTM) $ -0.36
Beta-0.13
Volatility417.04%
52-Week Range $2.35 - 23.34
Shares Outstanding (Mil)326.29 (ADR)

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 222 474 689 1,349
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.38 0.08 0.33 1.50
EPS without NRI ($) -0.38 0.08 0.33 1.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}